Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.48 |
| ▸ | PPARD | Q03181 | 12/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754314 | 0.86 | RARA (0.41) | FFAR1RARARARBMAPTLMNA | |
| SCHEMBL17754306 | 0.85 | MAPT (0.49) | MAPTALDH1A1LMNA | |
| SCHEMBL20312018 | 0.83 | GPR174 (0.41) | FFAR1PPARDRARARARBMAPT | |
| SCHEMBL19882314 | 0.83 | GPR174 (0.41) | FFAR1PPARDRARARARBMAPT | |
| SCHEMBL19636594 | 0.82 | FFAR1 (0.43) | FFAR1PPARDPPARANR1H4MAPT | |
| SCHEMBL21470071 | 0.81 | RARA (0.44) | FFAR1PPARDRARARARBPPARA | |
| SCHEMBL18503392 | 0.80 | FFAR1 (0.41) | FFAR1PPARDRARARARBPPARA | |
| SCHEMBL21469890 | 0.80 | RARB (0.42) | FFAR1PPARDRARARARBPPARA | |
| SCHEMBL20311779 | 0.80 | RARB (0.42) | FFAR1PPARDRARARARBPPARA | |
| SCHEMBL16982209 | 0.79 | POLB (0.48) | FFAR1PPARDRARARARBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | DIC CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | RCC1, LPXN, SMC4 | FFAR1 1525/4885PPARD 4473/4885RARA 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.